Cargando…
Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134059/ https://www.ncbi.nlm.nih.gov/pubmed/30206274 http://dx.doi.org/10.1038/s41598-018-31916-2 |
_version_ | 1783354603796955136 |
---|---|
author | Luetkens, Julian A. Wolpers, Anne C. Beiert, Thomas Kuetting, Daniel Dabir, Darius Homsi, Rami Meendermann, Hendrik Dayé, Natalie Abou Knappe, Vincent Karsdal, Morten Nielsen, Signe H. Genovese, Federica Stöckigt, Florian Linhart, Markus Thomas, Daniel Nickenig, Georg Schild, Hans H. Schrickel, Jan W. Andrié, René P. |
author_facet | Luetkens, Julian A. Wolpers, Anne C. Beiert, Thomas Kuetting, Daniel Dabir, Darius Homsi, Rami Meendermann, Hendrik Dayé, Natalie Abou Knappe, Vincent Karsdal, Morten Nielsen, Signe H. Genovese, Federica Stöckigt, Florian Linhart, Markus Thomas, Daniel Nickenig, Georg Schild, Hans H. Schrickel, Jan W. Andrié, René P. |
author_sort | Luetkens, Julian A. |
collection | PubMed |
description | To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation times were assessed using CMR. Plasma levels of relaxin, myeloperoxidase and serum levels of matrix metalloproteinase (MMP)-mediated cardiac specific titin fragmentation and MMP-mediated type IV collagen degradation were obtained. Poor outcome was defined by the recurrence of AF during 1-year follow-up. 61 patients were included in final analysis. Twenty (32.8%) patients had recurrence of AF. Patients with a recurrence of AF had a higher percentage of LA LGE (26.7 ± 12.5% vs. 17.0 ± 7.7%; P < 0.001), higher LA T1 relaxation times (856.7 ± 112.2 ms vs. 746.8 ± 91.0 ms; P < 0.001) and higher plasma levels of relaxin (0.69 ± 1.34 pg/ml vs. 0.37 ± 0.88 pg/ml; P = 0.035). In the multivariate Cox regression analysis, poor ablation outcome was best predicted by advanced LGE stage (hazard ratio (HR):5.487; P = 0.001) and T1 relaxation times (HR:1.007; P = 0.001). Pre-procedural CMR is a valuable tool for prediction of poor response to catheter ablation therapy in patients with AF. It offers various imaging techniques for outcome prediction and might be valuable for a better patient selection prior to ablation therapy. |
format | Online Article Text |
id | pubmed-6134059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61340592018-09-15 Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy Luetkens, Julian A. Wolpers, Anne C. Beiert, Thomas Kuetting, Daniel Dabir, Darius Homsi, Rami Meendermann, Hendrik Dayé, Natalie Abou Knappe, Vincent Karsdal, Morten Nielsen, Signe H. Genovese, Federica Stöckigt, Florian Linhart, Markus Thomas, Daniel Nickenig, Georg Schild, Hans H. Schrickel, Jan W. Andrié, René P. Sci Rep Article To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation times were assessed using CMR. Plasma levels of relaxin, myeloperoxidase and serum levels of matrix metalloproteinase (MMP)-mediated cardiac specific titin fragmentation and MMP-mediated type IV collagen degradation were obtained. Poor outcome was defined by the recurrence of AF during 1-year follow-up. 61 patients were included in final analysis. Twenty (32.8%) patients had recurrence of AF. Patients with a recurrence of AF had a higher percentage of LA LGE (26.7 ± 12.5% vs. 17.0 ± 7.7%; P < 0.001), higher LA T1 relaxation times (856.7 ± 112.2 ms vs. 746.8 ± 91.0 ms; P < 0.001) and higher plasma levels of relaxin (0.69 ± 1.34 pg/ml vs. 0.37 ± 0.88 pg/ml; P = 0.035). In the multivariate Cox regression analysis, poor ablation outcome was best predicted by advanced LGE stage (hazard ratio (HR):5.487; P = 0.001) and T1 relaxation times (HR:1.007; P = 0.001). Pre-procedural CMR is a valuable tool for prediction of poor response to catheter ablation therapy in patients with AF. It offers various imaging techniques for outcome prediction and might be valuable for a better patient selection prior to ablation therapy. Nature Publishing Group UK 2018-09-11 /pmc/articles/PMC6134059/ /pubmed/30206274 http://dx.doi.org/10.1038/s41598-018-31916-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Luetkens, Julian A. Wolpers, Anne C. Beiert, Thomas Kuetting, Daniel Dabir, Darius Homsi, Rami Meendermann, Hendrik Dayé, Natalie Abou Knappe, Vincent Karsdal, Morten Nielsen, Signe H. Genovese, Federica Stöckigt, Florian Linhart, Markus Thomas, Daniel Nickenig, Georg Schild, Hans H. Schrickel, Jan W. Andrié, René P. Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title | Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_full | Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_fullStr | Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_full_unstemmed | Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_short | Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_sort | cardiac magnetic resonance using late gadolinium enhancement and atrial t1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134059/ https://www.ncbi.nlm.nih.gov/pubmed/30206274 http://dx.doi.org/10.1038/s41598-018-31916-2 |
work_keys_str_mv | AT luetkensjuliana cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT wolpersannec cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT beiertthomas cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT kuettingdaniel cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT dabirdarius cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT homsirami cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT meendermannhendrik cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT dayenatalieabou cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT knappevincent cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT karsdalmorten cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT nielsensigneh cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT genovesefederica cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT stockigtflorian cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT linhartmarkus cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT thomasdaniel cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT nickeniggeorg cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT schildhansh cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT schrickeljanw cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT andrierenep cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy |